Ovarian Stimulation Clinical Trial
To analyse the impact on cycle outcome of LH supplementation in ovarian stimulation controlled with a GnRH antagonist in two ages groups: patients upto 35 years old, and patients aged between 36 and 39 years old.
All patients received an oral contraceptive pill with 0.030 mg of ethinyl-estradiol and 3.0
mg of drospirenone the cycle prior to ovarian stimulation. On the second day of
menstruation, patients started ovarian stimulation as follows:
Patients < 36: 225 IU/day of recombinant FSH (FSH alone group) or 150 IU of rFSH and 75 IU
of rLH/day (FSH+LH group) for 5 days. On day 6, a 0.25 mg/day dose of the GnRH antagonist
Cetrorelix is added until the day of rCG administration.
Patients 36-39: Initial dose of 300 IU of rFSH /day (FSH alone group)) or 225 IU of rFSH and
75 IU of rLH/day (FSH + LH group) for 5 days. On day 6, a 0.25 mg/day dose of the GnRH
antagonist Cetrorelix is added until the day of rCG administration.
A maximum of 3 embryos were transferred on day 3 of embryo development.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01121991 -
A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies
|
Phase 3 | |
| Not yet recruiting |
NCT04539067 -
Effect of Controlled Ovarian Stimulation in Quality of Oocyte and Embryo
|
Phase 2 | |
| Recruiting |
NCT02715336 -
Efficacy and Safety of Medication Used to Stimulate Ovulation
|
Phase 4 | |
| Not yet recruiting |
NCT03298750 -
Mechanical Stimulation of the Ovary for Infertility Treatment in Patients With Very Low Ovarian Reserve
|
N/A | |
| Completed |
NCT03939403 -
Conventional Ovarian Stimulation vs. Single Injection Stimulation of Corifollitropin Alfa in Oocyte Donor
|
Phase 4 | |
| Recruiting |
NCT06142708 -
The Effect of Dual Trigger (GnRH Agonist + hCG) for Final Maturation in Oocyte Donors With History of a Previous Cycle With Suboptimal Response to GnRH Agonist Only Trigger
|
N/A | |
| Recruiting |
NCT05166668 -
Letrozole /GnRH Antagonist Protocol in Women Over 40 Years Undergoing ICSI Cycle
|
N/A | |
| Completed |
NCT04549649 -
The Effect of Dual Trigger for Final Oocyte Maturation on IVF/ICSI Outcomes in Patients With Suboptimal Ovarian Response
|
N/A | |
| Terminated |
NCT01816789 -
Age Versus Ovarian Reserve Markers Based Therapy in IVF (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles
|
Phase 4 | |
| Completed |
NCT00823004 -
Antagonist/Letrozole in Poor Responders
|
Phase 1/Phase 2 | |
| Completed |
NCT00830492 -
Clomiphene Citrate (CC)/Gonadotropin/Gonadotropin Releasing Hormone (GnRH) Antagonist Versus Gonadotropin/GnRH Agonist
|
Phase 4 | |
| Completed |
NCT01145144 -
Dehydroepiandrosterone Supplementation for Poor Responder Patients During in Vitro Fertilization Treatment
|
N/A | |
| Completed |
NCT00829075 -
Impact of Three Different Gonadotrophin Regimes on Egg Donation Program
|
Phase 4 | |
| Completed |
NCT01112358 -
Lutropin Alfa in Women at Risk of Poor Response
|
Phase 2 | |
| Recruiting |
NCT03400722 -
Double Ovarian Stimulation as Accumulation Strategy for Older Infertile Patients With Suboptimal Ovarian Response
|
Phase 4 | |
| Not yet recruiting |
NCT06175832 -
PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study
|
Phase 4 | |
| Completed |
NCT00669786 -
Human Menopausal Gonadotropin (HMG) vs Recombinant Follicle Stimulating Hormone (rFSH) in Gonadotropin Releasing Hormone (GnRH) Antagonist Cycles
|
Phase 3 |